The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesICC: 1/200 - 1/500.
IF: Use at an assay dependent dilution. Use a secondary antibody conjugated to biotin and then streptavidin-conjugated to fluorochrome.
IHC (whole mounts): 1/4000 - 1/8000. Use in conjunction with MEMFA as fixative.
IHC-P: 1/250 - 1/1000.
IHC-Fr: 1/3000 - 1/6000.
WB: 1/2500 - 1/5000. Predicted molecular weight: 44 kDa.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionActs as a transcriptional activator. Binds to and activates the promoter of the alpha-glycoprotein gene, and synergistically enhances transcription from the prolactin promoter in cooperation with Pit-1.
Involvement in diseaseDefects in LHX3 are the cause of pituitary hormone deficiency combined type 3 (CPHD3) [MIM:221750]; also known as combined pituitary hormone deficiency with rigid cervical spine or sensorineural deafness with pituitary dwarfism. CPHD is characterized by a complete deficit in all but one (adrenocorticotropin) anterior pituitary hormone and a rigid cervical spine leading to limited head rotation.